Plus, news about Intra-Cellular:
Cerevance adds $47 million to Series B: The neurological disease biotech’s series B-1 raise now sits at $98 million, with investments from Agent Capital, Bioluminescence Ventures, and Double Point Ventures, among others. The company’s initial series B closed in 2020, but it raised $51 million in early 2023 as part of the B-1 raise. Cerevance said it plans to use the money towards its pipeline programs, including starting a Phase 3 clinical trial for a Parkinson’s disease drug. — Lei Lei Wu
Parexel signs AI partnership with Palantir: The contract clinical research company Parexel plans to use Palantir’s AI systems to “enhance and accelerate the delivery of safe and effective clinical trials for the world’s biopharmaceutical customers.” No terms of the partnership were disclosed. — Lei Lei Wu
Intra-Cellular closes $575M offering: The biotech raised the money after saying its drug cleared a Phase 3 test in patients with major depressive disorder. The shares $ITCI were sold at $73 apiece. — Kyle LaHucik